Skip to main content

FloLipid Side Effects

Generic name: simvastatin

Medically reviewed by Drugs.com. Last updated on Dec 4, 2023.

Note: This document contains side effect information about simvastatin. Some dosage forms listed on this page may not apply to the brand name FloLipid.

Applies to simvastatin: oral suspension, oral tablet.

Serious side effects of FloLipid

Along with its needed effects, simvastatin (the active ingredient contained in FloLipid) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking simvastatin:

More common

Less common

Incidence not known

Other side effects of FloLipid

Some side effects of simvastatin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to simvastatin: oral suspension, oral tablet.

General

The more commonly reported adverse effects have included upper respiratory infection, headache, abdominal pain, constipation, and nausea.[Ref]

Musculoskeletal

Common (1% to 10%): Myalgia

Uncommon (0.1% to 1%): Myopathy

Frequency not reported: Elevations in creatine kinase, myopathy, dermatomyositis, arthralgia, tendon rupture

Postmarketing reports: Muscle cramps, myalgia, rhabdomyolysis[Ref]

This drug causes dose-related myopathy which, in rare cases maybe severe and sometimes take the form of rhabdomyolysis with or without renal failure secondary to myoglobinuria; rarely fatalities have occurred. The incidence of myopathy with the 80 mg dose has been reported as disproportionately higher than that observed at lower doses and the risk of myopathy with simvastatin 80 mg/day is greater compared with other statins with similar or greater LDL-C lowering efficacy.[Ref]

Hepatic

Persistent elevations in transaminases of up to 3 times the upper limit of normal (3xULN) have been reported in 1% of patients. With therapy discontinuation or interruption, transaminase levels generally returned to pretreatment levels. There have been rare postmarketing reports of hepatic failure.[Ref]

Common (1% to 10%): Elevations in liver function tests

Frequency not reported: Hepatitis (including chronic active hepatitis), cholestatic jaundice, fatty changes in the liver, cirrhosis, hepatic failure, fulminant hepatic necrosis

Postmarketing reports: Hepatic failure, hepatitis, jaundice[Ref]

Gastrointestinal

Common (1% to 10%): Constipation, nausea, flatulence, diarrhea, dyspepsia, abdominal pain, gastritis

Frequency not reported: Anorexia

Postmarketing reports: Pancreatitis, vomiting[Ref]

Hematologic

Frequency not reported: Hemolytic anemia, thrombocytopenia, leucopenia, thrombotic thrombocytopenic purpura (TTP)

Postmarketing reports: Anemia[Ref]

Nervous system

Common (1% to 10%): Headache, vertigo

Frequency not reported: Cognitive impairment, cranial nerve dysfunction, tremor, vertigo, memory loss, paraesthesias, peripheral neuropathy, peripheral nerve palsy

Postmarketing reports: Dizziness, paresthesia, peripheral neuropathy, cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion)[Ref]

Renal

Frequency not reported: Myoglobinuria, acute renal failure secondary to rhabdomyolysis[Ref]

Cardiovascular

Common (1% to 10%): Angina, edema, atrial fibrillation[Ref]

Dermatologic

Common (1% to 10%): Eczema

Frequency not reported: Pruritic rash, erythema multiform including Stevens-Johnson syndrome, toxic epidermal necrolysis, photosensitivity, purpura

Postmarketing reports: Pruritus, alopecia, a variety of skin changes (e.g., nodules, discoloration, dryness of skin/mucous membranes, changes to hair/nails)[Ref]

Hypersensitivity

Frequency not reported: Anaphylaxis, angioedema, urticaria, fever, chills, flushing, malaise, dyspnea

Postmarketing reports: Hypersensitivity syndrome which has included some of the follow features: anaphylaxis, angioedema, lupus erythematous-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR increase, eosinophilia, arthritis, arthralgia, urticaria, asthenia, photosensitivity, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, erythema multiforme including Stevens-Johnson syndrome[Ref]

Immunologic

Postmarketing reports: Immune-mediated necrotizing myopathy[Ref]

Ocular

Frequency not reported: Progression of cataracts, ophthalmoplegia[Ref]

Psychiatric

Common (1%to 10%): Insomnia

Postmarketing reports: Depression[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection

Frequency not reported: Impotence, testicular pain, proteinuria

Postmarketing reports: Erectile dysfunction[Ref]

Oncologic

Frequency not reported: Tumor growth, liver, thyroid, lung adenomas, carcinomas[Ref]

Metabolic

Common (1% to 10%): Diabetes mellitus

Frequency not reported: HbA1c and fasting serum glucose levels elevations

Respiratory

Common (1% to 10%): Respiratory tract infection, bronchitis, sinusitis

Postmarketing reports: Interstitial lung disease

Other

Frequency not reported: Asthenia

Frequently asked questions

References

1. Halkin A, Lossos IS, Mevorach D. HMG-CoA reductase inhibitor-induced impotence. Ann Pharmacother. 1996;30:192.

2. Katznelson S. Immunosuppressive and antiproliferative effects of HMG-CoA reductase inhibitors. Transplant Proc. 1999;31:s22-4.

3. Katznelson S. Effect of HMG-CoA reductase inhibitors on chronic allograft rejection. Kidney Int. 1999;56:s117-21.

4. Walker JF. Simvastatin: the clinical profile. Am J Med. 1989;87:s44-6.

5. Simons LA. Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators. Clin Cardiol. 1993;16:317-22.

6. Bilheimer DW. Long-term clinical tolerance of lovastatin and simvastatin. Cardiology. 1990;77:58-65.

7. Product Information. Zocor (simvastatin). Merck & Co., Inc. 2001;PROD.

8. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med. 1993;94:109-10.

9. McDonagh J, Winocour P, Walker DJ. Musculoskeletal manifestations during simvastatin therapy. Br J Rheumatol. 1993;32:647-8.

10. Plosker GL, Mctavish D. Simvastatin - a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs. 1995;50:334-63.

11. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyorala K, Thorgeirsso. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the scandinavian simvastatin survival study. Arch Intern Med. 1996;156:2085-92.

12. Vanpuijenbroek EP, Dubufvereijken PWG, Spooren PFMJ, Vandoormaal JJ. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med. 1996;240:403-4.

13. van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med. 1996;240:403-4.

14. Alvarez JM, Rawdanowiz TJ, Goldstein J. Rhadbdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin. J Thorac Cardiovasc Surg. 1998;116:654-5.

15. Weise WJ, Possidente CJ. Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient. Am J Med. 2000;108:351-2.

16. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000;283:3205-10.

17. Khattak FH, Morris IM, Branford WA. Simvastatin-associated dermatomyositis. Br J Rheumatol. 1994;33:199.

18. ChoquetKastylevsky G, Kanitakis J, Dumas V, Descotes J, Faure M, Claudy A. Eosinophilic fasciitis and simvastatin. Arch Intern Med. 2001;161:1456-7.

19. Chan MH, Mak TW, Chiu RW, Chow CC, Chan IH, Lam CW. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab. 2001;86:4556-9.

20. Peces R, Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron. 2001;89:117-8.

21. Federman DG, Hussain F, Walters AB. Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J. 2001;94:1023-6.

22. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36:288-95.

23. Maxa JL, Melton LB, Ogu CC, Sills MN, Limanni A. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann Pharmacother. 2002;36:820-3.

24. Summaries for patients. Muscle abnormalities in four patients taking statins to treat unfavorable cholesterol levels. Ann Intern Med. 2002;137:I45.

25. Grundy SM. Can statins cause chronic low-grade myopathy? Ann Intern Med. 2002;137:617-8.

26. Sinzinger H, Wolfram R, Peskar BA. Muscular side effects of statins. J Cardiovasc Pharmacol. 2002;40:163-71.

27. Itakura H, Vaughn D, Haller DG, O'Dwyer PJ. Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer. J Urol. 2003;169:613.

28. Diaczok BJ, Shali R. Statins unmasking a mitochondrial myopathy: a case report and proposed mechanism of disease. South Med J. 2003;96:318-20.

29. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585-90.

30. Gonyeau MJ. Statins and osteoporosis: a clinical review. Pharmacotherapy. 2005;25:228-43.

31. Finsterer J, Zuntner G. Rhabdomyolysis from Simvastatin triggered by infection and muscle exertion. South Med J. 2005;98:827-9.

32. Mukhtar RY, Reckless JP. Statin-induced myositis: a commonly encountered or rare side effect? Curr Opin Lipidol. 2005;16:640-7.

33. Cerner Multum, Inc. UK Summary of Product Characteristics.

34. Arora R, Liebo M, Maldonado F. Statin-induced myopathy: the two faces of Janus. J Cardiovasc Pharmacol Ther. 2006;11:105-12.

35. Ramdass MJ, Singh G, Andrews B. Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism. Postgrad Med J. 2007;83:152-3.

36. Molden E, Andersson KS. Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. Pharmacotherapy. 2007;27:603-7.

37. Mauro VF, MacDonald JL. Simvastatin: a review of its pharmacology and clinical use. DICP. 1991;25:257-64.

38. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet. 1999;353:1763-4.

39. Chagnon JP, Cerf M. Simvastatin-induced protein-losing enteropathy. Am J Gastroenterol. 1992;87:257.

40. Johnson JL, Loomis IB. A case of simvastatin-associated pancreatitis and review of statin-associated pancreatitis. Pharmacotherapy. 2006;26:414-22.

41. Adverse Drug Reactions Advisory Committee (ADRAC) and the Adverse Drug Reactions Unit of the TGA. Australian Adverse Drug Reactions Bulletin. http://www.tga.gov.au/adr/aadrb/aadr0612.htm 2007.

42. Sundram F, Roberts P, Kennedy B, Pavord S. Thrombotic thrombocytopenic purpura associated with statin treatment. Postgrad Med J. 2004;80:551-2.

43. Phan T, Mcleod JG, Pollard JD, Peiris O, Rohan A, Halpern JP. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry. 1995;58:625-8.

44. Orsi A, Sherman O, Woldeselassie. Simvastatin-associated memory loss. Pharmacotherapy. 2001;21:767-9.

45. Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology. 2002;58:1333-7.

46. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117:823-9.

47. Morales K, Wittink M, Datto C, et al. Simvastatin causes changes in affective processes in elderly volunteers. J Am Geriatr Soc. 2006;54:70-6.

48. Gregoor PJ. Atorvastatin may cause nightmares. BMJ. 2006;332:950.

49. Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E. Short-term memory loss associated with rosuvastatin. Pharmacotherapy. 2006;26:1190-2.

50. Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother. 2006;40:1880-3.

51. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Thorgeirsson G, Pyorala K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.

52. Feldmann R, Mainetti C, Saurat JH. Skin lesions due to treatment with simvastatin (Zocor). Dermatology. 1993;186:272.

53. Krasovec M, Elsner P, Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology. 1993;186:248-52.

54. Bannwarth B, Miremont G, Papapietro PM. Lupuslike syndrome associated with simvastatin. Arch Intern Med. 1992;152:1093.

55. Rudski L, Rabinovitch MA, Danoff D. Systemic immune reactions to HMG-CoA reductase inhibitors - Report of 4 cases and review of the literature. Medicine. 1998;77:378-83.

56. Duits N, Bos FM. Depressive symptoms and cholesterol-lowering drugs. Lancet. 1993;341:114.

57. Linnebur SA, Hiatt WH. Probable Statin-Induced Testicular Pain (January). Ann Pharmacother. 2007.

58. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA. 1996;275:55-60.

59. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med. 2001;110:716-23.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer